Potenzial nach massiven Kurssturz Balchem (905650)
Seite 1 von 2 Neuester Beitrag: 25.10.24 21:56 | ||||
| Eröffnet am: | 02.04.12 18:40 | von: raketentrade. | Anzahl Beiträge: | 43 |
| Neuester Beitrag: | 25.10.24 21:56 | von: Tamakoschy | Leser gesamt: | 25.986 |
| Forum: | Hot-Stocks | Leser heute: | 19 | |
| Bewertet mit: |  | |||
| Seite: < | 2 > | ||||
A Downtrend for Balchem (NASDAQ:BCPC) on January 23rd, 2012 at $38.73. In approximately 2 months, Balchem has returned 22.67% as of today's recent price of $29.95.
Balchem share prices have moved between a 52-week high of $47.23 and a 52-week low of $26.56 and are now trading 13% above that low price at $29.95 per share. Over the last five market days, the 200-day moving average (MA) has gone down 0.4% while the 50-day MA has declined 2.1%.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. The Company micro-encapsulates performance ingredients, and also repackages and markets specialty gases. Balchem sells its products through its own sales force, independent distributors, and sales agents.
http://www.balchem.com/news/balchem-corporation-announces-fourth-quarter-2011-results
So schlecht schauen die Zahlen auch wieder nicht aus
aber trotzdem sehr interessant
Rosenheim (aktiencheck.de AG) - Die Experten von "boerse.de-Aktienbrief" nutzen den Aufwärtstrendwechsel bei der Aktie von Balchem (<US0576652004>/ <US0576652004>) zum Einstieg. Laut aktuellem Forbes-Ranking sei dieses US-Spezialchemieunternehmen die Nummer 29 unter "Americas best Small Companies". Schwerpunkte seien Nahrungsergänzungsmittel, Zusatzstoffe für die Pharmaindustrie, Tierfutter sowie medizintechnische Spezialerzeugnisse. Damit seien im dritten Quartal abermals Rekordergebnisse verbucht worden, wobei die Umsätze um 16% auf 74 Mio. USD gestiegen seien, während der Gewinn (11 Mio. USD) sogar um 27% nach oben geschnellt sei. Die Aktie glänze mit einem mustergültigen Kursverlauf von links unten nach rechts oben, der sich in hervorragenden Performance-Kennzahlen niederschlage. Seit 2001 sei Balchem mit einer hohen Gewinn-Konstanz im Schnitt 24% p.a. aufgesattelt, wobei die Verlust-Ratio von 2,09 unterdurchschnittlich ausfalle. Nach dem August-Rücksetzer gelang jetzt der erneute Aufwärtstrendwechsel bei der Balchem-Aktie, den die Experten von "boerse.de-Aktienbrief" zum zweiten Einstieg nutzen. Damit würden sie sich 12% Crash-Rabatt gegenüber dem Juli-All-Time-High sichern, und bis 2016 errechne sich eine Gewinn-Perspektive von 170%. (Ausgabe 253 vom 16.11.2011) (18.11.2011/ac/a/a)
http://www.fool.com/investing/general/2012/05/03/...timates-on-e.aspx
Balchem ( Nasdaq: BCPC ) reported earnings yesterday. Here are the numbers you need to
... (automatisch gekürzt) ...
http://www.fool.com/investing/general/2012/05/03/...timates-on-e.aspx
Zeitpunkt: 07.05.12 10:56
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen - Bitte nur kurz zitieren.
Original-Link: http://www.fool.com/investing/general/...stimates-on-e.aspx
The 10-second takeaway
For the quarter ended June 30 (Q2), Balchem beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.
Gross margins dropped, operating margins were steady, net margins dropped.
Revenue details
Balchem reported revenue of $79.0 million. The three analysts polled by S&P Capital IQ predicted revenue of $76.0 million on the same basis. GAAP reported sales were 5.8% higher than the prior-year quarter's $74.7 million.
http://www.balchem.com/news/...n-announces-third-quarter-2012-results
Optionen
| Boardmail an "Solventzo" |
Wertpapier: Balchem Corp |
About Balchem
Balchem Corporation consists of three business segments: ARC Specialty Products; SensoryEffects (formerly Food, Pharma & Nutrition); and Animal Nutrition & Health. Through ARC Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries. The SensoryEffects segment provides customized food and beverage ingredient systems and proprietary microencapsulation solutions to a variety of applications in the human food, pharmaceutical and nutrition marketplaces. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets and certain derivative products into industrial applications.
Forward-Looking Statements
This release contains forward-looking statements, which reflect Balchem's expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Balchem's expectations, including risks and factors identified in Balchem's annual report on Form 10-K for the year ended December 31, 2013. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.
http://finance.yahoo.com/news/...on-announces-dividend-200000807.html
letzten Tagen vermutlich den Weg nach Norden gewählt.
Die Aktie habe ich am 27.5.2014 für 41,34€ gekauft, heute steht sie 57,6€.
Wie ich gelesen habe, gilt sie als unterbewertet. Der Kurs scheint in Bewegung zu
kommen, und zwar in die richtige Richtung nach Norden und hat ein Hoch gebildet,
zudem kommt im Dez. die Div.-Zahlung. Die Höhe der bisherigen Zahlungen scheint
stetig nach oben zu gehen und dies kann ich als stabil bezeichnen. Ich glaube, eine
gute Kaufgelegenheit mit Signal.
Balchem Corporation Acquires Albion International, Inc.
NEW HAMPTON, N.Y., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Balchem Corporation (BCPC) today announced that it acquired Albion International, Inc., a privately held manufacturer of mineral amino acid chelates, specialized mineral salts and mineral complexes, headquartered in Clearfield, Utah for a purchase price of $111.5 million in cash. Albion’s 2015 revenues were approximately $53.5 million. The acquisition purchase price reflects a multiple of approximately 10.7 times 2015 EBITDA, excluding any synergies. The transaction consideration is subject to certain adjustments as provided in the definitive agreement. The purchase price will be financed through the Company’s existing revolving credit facility and cash on hand. The transaction is expected to be immediately accretive to Balchem’s earnings per share.
Albion has been a world leader and innovator in the manufacture of superior organic mineral compounds for sixty years. With over 100 patents, Albion leverages scientific expertise in the areas of both human and plant nutrition. Albion’s products are renowned in the supplement industry for technologically advanced, unparalleled bioavailability.
With this acquisition, Balchem continues to expand its science based human health and wellness solutions. Already the global leader in the essential nutrient, choline, Balchem will immediately expand the combined company's product offerings in the nutritional ingredient market by adding Albion’s premier branded innovative chelated minerals to its portfolio. The combined company will also benefit from a broader geographic footprint and an even stronger position as a technological leader in spray-drying and ingredient delivery solutions.
“We are very excited to add Albion’s deep scientific expertise, broad patent portfolio, and premium branded products to our company. This acquisition creates a broader nutritional platform for Balchem that will help our customers improve their nutritional and wellness solutions,” said Ted Harris, President and CEO of Balchem.
About Balchem
Balchem Corporation consists of four business segments: SensoryEffects; Animal Nutrition and Health; Specialty Products; and Industrial Products. The SensoryEffects segment provides customized food and beverage ingredient systems and proprietary microencapsulation solutions to a variety of applications in the human food, pharmaceutical and nutrition marketplaces. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and the Industrial Products segment, provides certain derivative products into industrial applications, predominately as a component for hydraulic fracturing of shale natural gas wells.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Balchem or SensoryEffects and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations and risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2014. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date, except as required by law.
Contact:
Balchem Contact:
Suzanne Hart, Investor Relations
Telephone: 845-326-5600
E-mail: bcpc-ir@balchem.com
Balchem Corporation Reports Record Adjusted Earnings Per Share of $2.51 for Full Year 2015; Fourth Quarter Adjusted Earnings Per Share of $0.66
http://seekingalpha.com/pr/...gs-per-share-2_51-full-year-2015-fourth
.
NEW HAMPTON, N.Y., May 10, 2016 (GLOBE NEWSWIRE) -- Balchem Corporation (BCPC) today reported for the first quarter 2016 adjusted EBITDA(a) of $35.5 million, compared to $36.1 million in the prior year quarter and $33.7 million sequentially from the fourth quarter 2015. Adjusted EBITDA margin expanded to 26.2% from 24.9% and 25.4% in the prior year quarter and fourth quarter 2015, respectively, and this was a significant contributor to these results in a challenging oil & gas and dairy market environment.
First Quarter 2016 Financial Highlights:
•Net sales of $135.1 million, a decrease of 6.7% compared to the first quarter of 2015, with the most significant driver of this decline being a $13.6 million reduction in sales in Industrial Products.
•Without the impact of Albion, record first quarter earnings for our Human Nutrition & Health (formerly SensoryEffects)(b) segment and record first quarter sales and record first quarter earnings for our Specialty Products(c) segment.
•Adjusted EBITDA margin improved to 26.2% versus 24.9% in the first quarter 2015 and 25.4% sequentially from the fourth quarter 2015 principally due to improved product mix and lower raw material costs.
•Adjusted earnings per share(a) of $0.58 decreased $0.04 or 6.5% from the prior year.
•Record first quarter cash flows from operations generated of $29.3 million.